Press releases
- Press releases
- Browse
Press releases
New summary from Partneringdesk highlights trends in dealmaking from the top pharma and biotech companies More
Robarts Clinical Trials at The University of Western Ontario has been awarded a $4.7 million grant to conduct a randomized controlled trial evaluating treatment options for Crohn's disease. More
SGS announces the acquisition of aster.cephac headquartered in Paris, France. More
BioXell S.p.A. and Lay Line Genomics S.p.A. (LLG) today announced an exclusive, worldwide license agreement for the development of MNAC13, a novel humanized monoclonal antibody that binds to TrkA receptors, blocking the action of Nerve Growth Factor More
Related Reports
Market Research Reports provided by reports.iptechex.com
Dec 2010 - 37 pages - $500
Apr 2011 - 75 pages - $3,800
May 2011 - 15 pages - $250
Nov 2010 - 40 pages - $500
Sep 2011 - 95 pages - $3,500
Feb 2011 - 26 pages - $1,000
Apr 2011 - 33 pages - $1,000
Mar 2011 - 29 pages - $1,000
Dec 2010 - 22 pages - $500
Jan 2011 - 34 pages - $500
Your selection
Browse By
- Therapeutic target
- Adoptive immunotherapy
- Amyloidosis
- Autoimmune disease (non-specific)
- Chronic fatigue syndrome
- Chronic granulomatous disease
- Chronic immunosuppression
- Gout
- Graft versus host disease
- HIV/AIDS
- Immune disorder (non-specific)
- Immune thrombocytopenic purpura
- Immunomodulation
- Immunostimulation
- Immunosuppression
- Lupus erythematosis
- Myalgic encephalomyelitis
- Myasthenia gravis
- Neoplastic disease
- Organ transplant rejection
- Rheumatoid arthritis
- Servere combined immunodeficency
- Sjogren's syndrome
- Systemic sclerosis
- Transplant rejection
- Xenotransplantation
- Year
- 2013
- 2012
- 2011
- 2010
- 2009
- 2008
- 2007
- 2006
- 2005
- 2004
- 2003
- 2002
- 2001
- 2000
- 1999
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us